Companies
Northeast Pharmaceutical
one of the world's three leading vitamin C suppliers, reported in March 2026 that its plants were running at full capacity, with vitamin C and piracetam output up nearly 15% year-on-year in the first two months of the year and core products passing multiple international customer audits.
- Country
- China
- Ticker
- 000597.SZ
vitamin-c
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsfdaefsanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | 2.006 billion yuan (Q1 2026) | disc.static.szse.cn |
| Headcount | 5,727 (as of Dec 31, 2025) | stockanalysis.com |
| Production site | two major production bases for active pharmaceutical ingredients and formulations (910,000 sqm and 180,000 sqm respectively) | nepharm.com |
| Capacity | plants running at full capacity (as of March 2026) | ln.xinhuanet.com |
| Certification | EDQM, FDA, Japan MHLW, BRC, HALAL, KOSHER, ISO9001, FAMI-QS | nepharm.com |
| Regulatory approval | DCTY0801 injection clinical trial approval (2025); FDA orphan drug designation (2023) | static.cninfo.com.cn · disc.static.szse.cn |
Independent sources: disc.static.szse.cn · ln.xinhuanet.com · nepharm.com · static.cninfo.com.cn · stockanalysis.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Vitamins (D3, B-group, ascorbic acid) | food-alt-protein | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.